Mastermind Session: Advancing rhPSMA from Early Clinical Promise to Registrational Success: Overcoming the Phase I–III Bottleneck

2:30 pm - Thursday 3rd December 2026

Leveraging early clinical efficacy, safety and dosimetry data to make confident programme progression decisions and strengthen Phase II/III development strategies
Aligning clinical, CMC and operational planning early to minimise execution risk and support globally scalable registrational trials
Optimising trial design, patient selection and endpoint strategies to generate clinically meaningful data that satisfies regulators, payers and clinicians